Canadian Active Drug Post Marketing Observational Epidemiological Study : Assessing an Active Drug Real-life Effectiveness and Impact on HS Burden of Illness

Brief summary

This study assesses an active drug real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).

Observational study

Hidradenitis Suppurativa (HS)
165 patients
Protocol ID:
Observational model:
Time perspective:

Would you like to know more about this trial?

Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female


From 18 Years to 99 Years.

Inclusion Criteria:

- Has a clinical diagnosis of moderate to severe HS according to the treating physician

- Need a change in ongoing therapy for any reason, but not limited to inadequate
response, intolerance, sub-optimal compliance, or patient preference. Patient will be
approached to participate in the study after a decision to change patient's therapy
for Humira® is made by the treating physician.

- Has provided written informed consent (Patient Authorization) for participation in the

Exclusion Criteria:

- Is participating in a clinical interventional study

- Was treated with Humira®, or any other biologic agents for HS prior to baseline visit

- Has any other active skin disease or condition that, in the opinion of the treating
physician, prohibits the patient from participating in the study or obscures the
assessment of the treatment of HS

All the cities where the clinical studies are located